Ask AI
Beyond A1C in T2D TM 3

CE / CME

Looking Beyond A1C in T2D Care: Evidence Integration and Clinical Positioning

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: August 07, 2026

Expiration: August 06, 2027

Activity

Progress
1 2 3
Course Completed

References

  1. Liraglutide [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc.; 2025.
  2. Semaglutide [prescribing information]. Plainsboro, NJ: Novo Nordisk, Inc.; 2026.
  3. Dulaglutide [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2026.
  4. Orforglipron [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2026.
  5. Writing Committee Members; Ndumele CE, Rodriguez F, Dixon DL, et al. 2026 AHA/ACC/ADA/ASN guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome: a Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;154:e50-e158.
  6. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105:S117-S314.
  7. American Diabetes Association Professional Practice Committee for Diabetes*. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S183-S215.
  8. Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2022;12:145.
  9. Hu Z, Tian D, Yang Z, et al. The mechanisms of GLP-1 receptor agonists in liver diseases: their multifaceted impact on immune response and metabolic regulation. Front Pharmacol. 2026;17:1754721.
  10. Tirzepatide [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2026.
  11. Ludinard A, Chrusciel J, Sanchez S. Referral reasons of type 2 diabetes patients from general practitioners to diabetes specialists: a cross-sectional observational study. BMC Prim Care. 2025;26: 105.